COMMUNIQUÉS West-GlobeNewswire

Chiesi Global Rare Diseases Launches “Rethink Acromegaly” Campaign to Provide Important Disease Education and Support to the Acromegaly Community

01/03/2024 - 14:30

Rethink Acromegaly is created by Chiesi and members of the acromegaly community to help people living with the condition, along with their caregivers and families, to make informed healthcare decisions Program includes [...]

Dyadic to Attend Industry Events in March

01/03/2024 - 14:30

JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the [...]

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

01/03/2024 - 14:30

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate’s previously [...]

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

01/03/2024 - 14:30

- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of eight months and one [...]

Empowering the Future of Healthcare: How Healthcare Triangle's AI Initiative Sets a New Standard in Patient Care Excellence

01/03/2024 - 14:30

PLEASANTON, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” HCTI” or the “Company”), embarks on a major initiative to integrate Artificial Intelligence (AI) and [...]

Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024

01/03/2024 - 14:30

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS

01/03/2024 - 14:00

– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to initiate in 1H 2024 [...]

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

01/03/2024 - 14:00

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

01/03/2024 - 14:00

-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus; expect to [...]

Fate Therapeutics to Present at Upcoming March Investor Conferences

01/03/2024 - 14:00

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of [...]

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

01/03/2024 - 14:00

HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to [...]

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

01/03/2024 - 14:00

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected in March 2024; [...]

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

01/03/2024 - 13:30

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI [...]

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

01/03/2024 - 13:00

NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and [...]

iTeos to Participate in Upcoming Investor Conferences

01/03/2024 - 13:00

WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]

iTeos annonce sa participation aux prochaines journées Investisseurs

01/03/2024 - 13:00

WATERTOWN, Massachusetts et GOSSELIES, Belgique, 01 mars 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

01/03/2024 - 13:00

Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of CLN-619 alone and in [...]

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024

01/03/2024 - 13:00

PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. Cowen [...]

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

01/03/2024 - 13:00

HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]